Viatris

Viatris

Yahoo Finance • 2 days ago

Viatris (VTRS) Stock Sees Modest Fair Value Lift After Q1 Results And Pipeline Progress

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. The latest research on Viatris centers on a revised price target of US$22 per share and what tha... Full story

Yahoo Finance • 9 days ago

Earnings scorecard: eight out of nine healthcare companies deliver EPS wins this week

Healthcare stocks (XLV [https://seekingalpha.com/symbol/XLV]) grabbed the spotlight this week as Wall Street digested earnings reports from companies including Centene (CNC [https://seekingalpha.com/symbol/CNC]), DexCom (DXCM [https://seek... Full story

Yahoo Finance • 17 days ago

3 Healthcare Stocks We Keep Off Our Radar

3 Healthcare Stocks We Keep Off Our Radar Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and th... Full story

Yahoo Finance • 18 days ago

Stock index futures edge higher as investors seek rebound after Thursday selloff

[Wall Street New York stock exchange stock market] alexsl Stock index futures were higher on Friday as the stock market hoped to recover from Thursday's selloff. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) +0.33%, S&P 500... Full story

Yahoo Finance • 24 days ago

Financial Stocks Rally To New Highs. JPMorgan Is One Of Them.

JPMorgan Chase stock and two other financial names hit new highs. A pharmaceutical stock also reached a high and is in a buy zone. Continue Reading... Full story

Yahoo Finance • last month

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Choosing between Novartis AG (NYSE:NVS) and Teva Pharmaceutical Industries (NYSE:TEVA) requires weighing the stability of an established innovator against the potential of a generic specialist undergoing a significant turnaround. Novartis... Full story

Yahoo Finance • last month

3 Dirt Cheap Healthcare Shares Under $30 to Buy Right Now

Quick Read Pfizer's 7% yield and forward P/E of 8 complement Viatris's three FDA PDUFA decisions arriving before year-end 2026. Kimberly-Clark's pending acquisition of Kenvue at $3.50 cash plus shares gives holders a defined takeout floor... Full story

Yahoo Finance • last month

Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

Key Points Eli Lilly and dominance in weight loss and diabetes treatments continues to fuel massive revenue growth. Teva Pharmaceutical Industries offers a value-oriented play as it moves past legal hurdles and expands its biosimilar port... Full story

Yahoo Finance • last month

Viatris (VTRS) Secures Loan Amid Positive Phase 3 Results

Viatris Inc. (NASDAQ:VTRS) is one of the Top 10 Extreme Value Stocks To Buy Now. On July 1, Viatris Inc. (NASDAQ:VTRS) entered into a loan agreement with a group of lenders led by Mizuho Bank. The company secured a ¥40 billion senior unsec... Full story

Yahoo Finance • 2 months ago

ISCV vs. IWN: Which Small-Cap Value ETF Is the Better Buy?

While both funds target smaller U.S. companies that appear undervalued relative to the broader market, the iShares Morningstar Small-Cap Value ETF (NYSEMKT:ISCV) provides that exposure to the small-cap value space at a lower cost than the... Full story

Yahoo Finance • 2 months ago

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds

1 Cash-Producing Stock with Exciting Potential and 2 Facing Headwinds A company that generates cash isn't automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luckily for y... Full story

Yahoo Finance • 2 months ago

Viatris Recognized as One of the 2026 Best Workplaces™ in Canada

ETOBICOKE, ON, June 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) has been recognized as one of the 2026 Best Workplaces™ in Canada by Great Place to Work®. This recognition highlights Viatris' commitment to fostering a culture wher... Full story

Yahoo Finance • 2 months ago

Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?

Investors deciding between Lexicon Pharmaceuticals(NASDAQ:LXRX) and Pfizer(NYSE:PFE) face a choice between an emerging high-growth biotech player and an established global pharmaceutical titan with massive scale. These two companies opera... Full story

Yahoo Finance • 2 months ago

Q4 Earnings Highlights: Amneal (NASDAQ:AMRX) Vs The Rest Of The Generic Pharmaceuticals Stocks

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Amneal (NASDAQ:AMRX) and the best and worst performers in the generic pharmaceutic... Full story

Yahoo Finance • 3 months ago

Acute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsight

The acute myocardial infarction market is experiencing steady growth driven by rising global cardiovascular disease prevalence and expanding geriatric populations. Advances in diagnostic technologies and rapid-acting therapies are accelera... Full story

Yahoo Finance • 3 months ago

TrumpRx set to expand into generic medicines with Mark Cuban

Heather Diehl/Getty Images News * Mark Cuban, the billionaire co-founder of the Cost Plus Drugs online pharmacy, is expected to join President Trump Monday afternoon as part of an announcement that the TrumpRx website will now carry gen... Full story

Yahoo Finance • 3 months ago

Most healthcare companies report higher Y/Y EPS in strong earnings week

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images Healthcare companies delivered strong earnings this week, with 18 out of 20 companies beating EPS estimates and 15 t... Full story

Yahoo Finance • 3 months ago

Chris Davis Significantly Reduces Stake in Applied Materials Inc, Impacting Portfolio by -3.47%

This article first appeared on GuruFocus. Insight into Chris Davis (Trades, Portfolio)'s Strategic Moves in Q1 2026 Warning! GuruFocus has detected 4 Warning Sign with AIG. Is COF fairly valued? Test your thesis with our free DCF calcula... Full story

Yahoo Finance • 3 months ago

Cardiogenic Shock Analysis Report 2026: Market to Reach $5.2 Billion by 2030, Driven by Minimally Invasive Techniques, AI Adoption. and Aging Populations

Dublin, May 07, 2026 (GLOBE NEWSWIRE) -- The "Cardiogenic Shock Market: 2026 Edition" has been added to ResearchAndMarkets.com's offering. The global cardiogenic shock market value in 2024 stood at US$3.57 billion, and is projected to... Full story

Yahoo Finance • 3 months ago

Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard

[Magnifying Glass On Top Of Bar Chart] DNY59 Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue i... Full story